Trial to Assess Whether Tyme Therapy or Monitoring Is Better for Prostate Cancer Patients

Trial to Assess Whether Tyme Therapy or Monitoring Is Better for Prostate Cancer Patients
A clinical trial will assess whether Tyme Technologies’ SM-88 is a better treatment option than active surveillance for prostate cancer patients who have not had surgery, radiation, or chemotherapy. Tyme has asked an expert in prostate cancer treatment, Mack Roach III of the University of California at San Francisco, to lead the study. SM-88 consists of three different

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *